Christoph Schaefers

Hamburg, HH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort.

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort.

Journal: Leukemia & lymphoma

Published: July 28, 2026

Adaptive bridging and holding therapy frequently reduces tumor burden and is associated with reduced toxicity after CAR-T cell therapy in multiple myeloma: A single-center real-world experience.

Adaptive bridging and holding therapy frequently reduces tumor burden and is associated with reduced toxicity after CAR-T cell therapy in multiple myeloma: A single-center real-world experience.

Journal: Transplantation and cellular therapy

Published: June 21, 2026

Supportive care for talquetamab-related dysgeusia in multiple myeloma: mixed-methods evidence, nutrition-focused flowchart, and digital companion concept.

Supportive care for talquetamab-related dysgeusia in multiple myeloma: mixed-methods evidence, nutrition-focused flowchart, and digital companion concept.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: February 20, 2026

Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysis.

Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysis.

Journal: Annals of hematology

Published: February 18, 2026

How to approach the high-risk myeloma from induction through relapse?

How to approach the high-risk myeloma from induction through relapse?

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis.

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis.

Journal: American journal of hematology

Published: December 02, 2025

Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

Journal: Blood cancer journal

Published: November 01, 2025

Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches.

Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches.

Journal: Haematologica

Published: June 03, 2025

Extramedullary plasmacytoma in children is a genetically distinct localized neoplasia curable by surgical resection.

Extramedullary plasmacytoma in children is a genetically distinct localized neoplasia curable by surgical resection.

Journal: Blood advances

Published: March 28, 2025

Evaluation of smoking status as a prognostic factor under immune checkpoint inhibitor treatment: A single center analysis.

Evaluation of smoking status as a prognostic factor under immune checkpoint inhibitor treatment: A single center analysis.

Journal: Oncology letters

Published: March 26, 2025

Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

Journal: Blood cancer journal

Published: March 11, 2025

Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy.

Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy.

Journal: Blood cancer discovery

Published: February 06, 2025

Showing 1-12 of 22

Last Updated: 09/26/2026